Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eusebio

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Pharmaceutical Research|April 2, 1998
Risedronate gastrointestinal absorption is independent of site and rate of administrationD Y Mitchell, R A Eusebio, L E Dunlap, et al.
Revue Neurologique|May 3, 2017
Parkinson's disease associated with 22q11.2 deletion: Clinical characteristics and response to treatmentB Dufournet, K Nguyen, P Charles, et al.
Pharmaceutical Research|June 19, 2001
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administrationD Y Mitchell, W H Barr, R A Eusebio, et al.
Journal of Clinical Pharmacology|March 10, 2000
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteersD Y Mitchell, R A Eusebio, N A Sacco-Gibson, et al.
Revue Neurologique|March 14, 2020
Prevalence and characterisation of vocal fold motion impairment (VFMI) in patients with Multiple system atrophy compared with Parkinson's diseaseS Grimaldi, M Renaud, D Robert, et al.
British Journal of Clinical Pharmacology|March 16, 2000
Effect of renal function on risedronate pharmacokinetics after a single oral doseD Y Mitchell, J V St Peter, R A Eusebio, et al.
Journal of Clinical Medicine|August 28, 2025
Retinal Thinning in Attention Deficit Hyperactivity Disorder (ADHD): Structural Changes Detected by Spectral-Domain OCTCarmen Miquel-Lopez, Jose Javier Garcia-Medina, A Eusebio Lopez-Hernandez, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 4, 2012
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataM R McClung, J R Zanchetta, A Racewicz, et al.
Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.
The European Journal of Neuroscience|July 29, 2008
Suppression of beta oscillations in the subthalamic nucleus following cortical stimulation in humansL M F Doyle Gaynor, A A Kühn, M Dileone, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Pharmaceutical Research|April 2, 1998
Risedronate gastrointestinal absorption is independent of site and rate of administrationD Y Mitchell, R A Eusebio, L E Dunlap, et al.
Revue Neurologique|May 3, 2017
Parkinson's disease associated with 22q11.2 deletion: Clinical characteristics and response to treatmentB Dufournet, K Nguyen, P Charles, et al.
Pharmaceutical Research|June 19, 2001
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administrationD Y Mitchell, W H Barr, R A Eusebio, et al.
Journal of Clinical Pharmacology|March 10, 2000
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteersD Y Mitchell, R A Eusebio, N A Sacco-Gibson, et al.
Revue Neurologique|March 14, 2020
Prevalence and characterisation of vocal fold motion impairment (VFMI) in patients with Multiple system atrophy compared with Parkinson's diseaseS Grimaldi, M Renaud, D Robert, et al.
British Journal of Clinical Pharmacology|March 16, 2000
Effect of renal function on risedronate pharmacokinetics after a single oral doseD Y Mitchell, J V St Peter, R A Eusebio, et al.
Journal of Clinical Medicine|August 28, 2025
Retinal Thinning in Attention Deficit Hyperactivity Disorder (ADHD): Structural Changes Detected by Spectral-Domain OCTCarmen Miquel-Lopez, Jose Javier Garcia-Medina, A Eusebio Lopez-Hernandez, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 4, 2012
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataM R McClung, J R Zanchetta, A Racewicz, et al.
Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.
The European Journal of Neuroscience|July 29, 2008
Suppression of beta oscillations in the subthalamic nucleus following cortical stimulation in humansL M F Doyle Gaynor, A A Kühn, M Dileone, et al.
Pageof 5